ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2011 | $1,330,000 | Replaced |
| 1st Quarter - Amendment | Aug 10, 2011 | $1,350,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to reform of tax code and possible timing of any such reform (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANNY LY | — |
Copyright/Patent/Trademark CPT
HR 6331 - patent issues associated with anti-biotics S. 3677, HR 4899 - legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Participate in executive branch discussions regarding intellectual property issues arising in foreign countries
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW KAPLAN | — |
| DANNY LY | — |
| BRADLEY ALLEN ROSSIN | — |
Health Issues HCR
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN New | Leg. Dir. Rep. Mike Rogers (MI) 1/01 - 3/05 |
Medicare/Medicaid MMM
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization Issues related to identification and correction of medical edit codes
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| RICHARD WAYNE OLSON | — |
Consumer Issues/Safety/Products CSP
S. 525 and related legislative proposals regarding prescription drug importation and safety issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN New | Leg. Dir. Rep. Mike Rogers (MI) 1/01 - 3/05 |
Pharmacy PHA
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW KAPLAN | — |
| DANNY LY | — |
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN New | Leg. Dir. Rep. Mike Rogers (MI) 1/01 - 3/05 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.